Article
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Journal of the National Cancer Institute - 8 Dec 2022
Rodriguez Cristina P, Kang Hyunseok, Geiger Jessica L, Burtness Barbara, Chung Christine H, Pickering Curtis R, Fakhry Carole, Le Quynh Thu, Yom Sue S, Galloway Thomas J, Golemis Erica, Li Alice, Shoop Jeffrey, Wong Stuart, Mehra Ranee, Skinner Heath, Saba Nabil F, Flores Elsa R, Myers Jeffrey N, Ford James M, Karchin Rachel, Ferris Robert L, Kunos Charles, Lynn Jean M, Malik Shakun
Abstract excerpt
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus-negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.